Treatment of DVT in c-ANCA Associated Vasculopathy
Treat the DVT with standard anticoagulation (LMWH, fondaparinux, or direct oral anticoagulants) for at least 3 months while simultaneously managing the underlying ANCA-associated vasculitis with immunosuppression (glucocorticoids plus rituximab or cyclophosphamide).
Understanding the Clinical Context
Venous thromboembolism (VTE), including DVT, occurs with increased frequency in patients with ANCA-associated vasculitis (AAV), particularly during periods of active disease 1, 2. The thrombotic risk appears to be driven by the inflammatory vasculitis itself rather than traditional VTE risk factors 2. This creates a dual treatment imperative: address both the thrombosis and the underlying autoimmune disease.
Primary Treatment Strategy
For the DVT Component:
Standard anticoagulation is required following established VTE guidelines 3:
- Initial therapy: LMWH, fondaparinux, or direct oral anticoagulants (if no contraindications)
- Minimum duration: 3 months of therapeutic anticoagulation 3
- Extended therapy consideration: Given that AAV represents an ongoing inflammatory/prothrombotic state, consider extended anticoagulation beyond 3 months if vasculitis remains active or incompletely controlled
For the Underlying AAV:
The vasculitis itself must be aggressively treated, as active disease perpetuates the prothrombotic state 2:
For organ-threatening or life-threatening disease (which includes patients with DVT complications):
- Glucocorticoids combined with either rituximab OR cyclophosphamide for remission induction 4, 5
- The 2024 KDIGO guidelines (most recent) recommend glucocorticoids plus rituximab or cyclophosphamide as first-line therapy 5
Specific dosing 5:
- Rituximab: 375 mg/m² weekly × 4 weeks
- Cyclophosphamide: Either oral 2 mg/kg/day for 3 months OR IV 15 mg/kg at weeks 0,2,4,7,10,13
- Glucocorticoids: Use reduced-dose regimens (starting 50-75 mg prednisolone based on weight, rapidly tapering) 5
Critical Management Considerations
Bleeding Risk with Dual Therapy
The combination of anticoagulation and immunosuppression (particularly with glucocorticoids) increases bleeding risk. However, do not withhold anticoagulation - the thrombotic risk from active vasculitis outweighs bleeding concerns in most cases.
Plasma Exchange Consideration
If the patient has severe renal involvement (creatinine ≥500 μmol/L or 5.7 mg/dL) or life-threatening manifestations, add plasma exchange 4. This addresses the severe vasculitis but does not replace anticoagulation for the DVT.
Duration of Anticoagulation
- Minimum 3 months is standard for provoked VTE 3
- Consider extended anticoagulation (potentially indefinite) if:
- Vasculitis remains active beyond 3 months
- Patient has recurrent disease activity
- Additional VTE risk factors are present
The decision to extend beyond 3 months should be reassessed once the vasculitis achieves remission, typically after 3-6 months of immunosuppressive therapy.
Maintenance Phase
After achieving remission (typically 3-6 months):
- Continue maintenance immunosuppression: Low-dose glucocorticoids plus azathioprine, rituximab, methotrexate, or mycophenolate for at least 24 months 4
- Reassess anticoagulation: If vasculitis is in sustained remission and no other VTE risk factors exist, anticoagulation can potentially be stopped after 3 months
Common Pitfalls to Avoid
- Do not delay anticoagulation while waiting for vasculitis workup or biopsy confirmation
- Do not attribute DVT solely to immobility or other factors - recognize AAV as the primary driver
- Do not use ANCA titers alone to guide treatment decisions; use clinical assessment 4, 5
- Do not undertreate the vasculitis thinking anticoagulation alone will suffice - both conditions require specific therapy
- Ensure Pneumocystis prophylaxis (trimethoprim-sulfamethoxazole) with cyclophosphamide therapy 6
Monitoring Requirements
- Weekly CBC initially during cyclophosphamide therapy
- Regular renal function and urinalysis monitoring
- Clinical assessment for bleeding complications
- Structured clinical examination rather than serial ANCA testing for treatment decisions 4, 5
This dual-pronged approach addresses both the immediate thrombotic complication and the underlying inflammatory driver, optimizing outcomes for mortality, morbidity, and quality of life.